The unique economics of Novavax manufacturing in single-use bioreactor systems is such that the need for large central facilities to drive low cost of goods is eliminated. Instead, smaller facilities can be built and operated economically and hence distributed to regions that need a local supply of influenza vaccine. This is particularly important to pandemic influenza supply as vaccine access is expected to be limited in the event of a pandemic and countries may have a desire to be self-sufficient within their border, rather than depending on foreign suppliers and importation issues during a pandemic event.